10-Q: Genprex Reports Second Quarter 2024 Results, Cites Progress in Clinical Trials

Genprex, Inc. reported its financial results for the second quarter of 2024, highlighting advancements in its clinical trials and a reduction in operating expenses.

Summary

• Genprex, Inc. released its financial results for the quarter ended June 30, 2024, showing a net loss of $6.5 million, compared to a net loss of $8.0 million for the same period in 2023.
• The company's research and development expenses decreased to $1.7 million from $4.0 million year-over-year, primarily due to changes in contract manufacturing and cost-cutting measures.
• General and administrative expenses increased slightly to $4.8 million from $4.1 million year-over-year, due to separation agreement payments, a change in accounting policy, and increased share-based compensation.
• Genprex's cash and cash equivalents totaled $2.5 million as of June 30, 2024, down from $6.7 million at the end of 2023.
• The company believes its current cash will fund operations into September 2024 and will need to raise additional capital to continue operations.
• Genprex is actively enrolling patients in its Acclaim-1 and Acclaim-3 clinical trials, with the first patient in the Acclaim-3 trial showing an initial positive response.
• The company has ceased enrollment in the Acclaim-2 trial to focus resources on the other two Acclaim trials.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there are positive developments in clinical trials and cost-cutting measures, the company's financial position is weak, and there is a going concern warning. The need for additional capital and the cessation of one trial are concerning.

Positives

• The company's net loss decreased by 19% year-over-year for the three months ended June 30, 2024.
• Research and development expenses were reduced by 58% year-over-year for the three months ended June 30, 2024.
• The first patient in the Acclaim-3 trial showed a positive initial response, suggesting potential clinical benefit from REQORSA.
• Genprex successfully raised $5.8 million through a registered direct offering in March 2024.
• The company is actively enrolling patients in the Acclaim-1 and Acclaim-3 clinical trials.

Negatives

• Genprex's cash and cash equivalents decreased to $2.5 million as of June 30, 2024, from $6.7 million at the end of 2023.
• The company has a going concern warning due to recurring losses and the need for additional financing.
• General and administrative expenses increased by 20% year-over-year for the three months ended June 30, 2024.
• The company has ceased enrollment in the Acclaim-2 trial due to enrollment challenges and delays.
• The company's current cash is only expected to fund operations into September 2024.

Risks

• Genprex faces the risk of not being able to raise additional capital, which could adversely affect its clinical trials and operations.
• The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing.
• There is a risk of delays in clinical trials, which could impact the company's financial resources and timelines.
• The company is dependent on third-party suppliers and manufacturers, which could lead to supply chain issues.
• The company is subject to the risk of not obtaining regulatory approvals for its product candidates.
• The company is subject to the risk of not being able to compete effectively with larger and better-financed companies.

Future Outlook

Genprex expects to complete the Phase 1 dose escalation portion of the Acclaim-3 study and start the Phase 2 expansion portion in the second half of 2024. The company also expects to complete the enrollment of the first 19 patients in the Phase 2a expansion portion of the Acclaim-1 study and conduct an interim analysis in the first half of 2025. The company anticipates requesting further regulatory guidance from the FDA in the first half of 2025 for its diabetes program.

Management Comments

• The company believes that the initial positive response in the Acclaim-3 trial suggests that REQORSA may be providing clinical benefit.
• Management is actively engaged in remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.
• The company is focused on prioritizing resources on the Acclaim-1 and Acclaim-3 trials.

Industry Context

Genprex is operating in the competitive biotechnology industry, focusing on gene therapy for cancer and diabetes. The company's approach of combining its therapy with existing treatments is a common strategy in the field. The company is facing competition for clinical trial enrollment, which is a common challenge in the industry.

Comparison to Industry Standards

• Genprex's cash burn rate is high, which is typical for clinical-stage biotech companies, but the company's cash reserves are low compared to industry benchmarks.
• The reduction in R&D expenses is a positive sign, but the increase in G&A expenses is a concern, as many companies in this sector focus on keeping G&A costs low.
• The initial positive response in the Acclaim-3 trial is encouraging, but the company needs to demonstrate consistent results across a larger patient population.
• The decision to cease enrollment in the Acclaim-2 trial is a strategic move to focus resources, which is a common practice in the industry when facing enrollment challenges.
• The company's reliance on external funding is a common risk for biotech companies, but the company's current cash runway is shorter than many of its peers.

Management Changes

Corporate Governance

Related Party Transactions

• There were no amounts incurred or due under the Assignment and Collaboration Agreement with Introgen Research Institute at June 30, 2024 and December 31, 2023.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future capital raises.
• Employees may be affected by cost-cutting measures and potential restructuring.
• Patients may benefit from the company's clinical trials, but there is a risk of delays and setbacks.
• Suppliers and creditors may be affected by the company's financial instability.

Next Steps

• Genprex will continue enrolling patients in the Acclaim-1 and Acclaim-3 clinical trials.
• The company expects to complete the Phase 1 dose escalation portion of the Acclaim-3 study and start the Phase 2 expansion portion in the second half of 2024.
• The company expects to complete the enrollment of the first 19 patients in the Phase 2a expansion portion of the Acclaim-1 study and conduct an interim analysis in the first half of 2025.
• The company anticipates requesting further regulatory guidance from the FDA in the first half of 2025 for its diabetes program.
• The company will seek additional funding to continue operations.

Key Dates

Keywords

Genprex, gene therapy, clinical trials, Reqorsa, lung cancer, diabetes, Oncoprex Delivery System, TUSC2, financial results, biotechnology